المؤلفون: Vavalà, Tiziana, Novello, Silvia

المساهمون: Vavalà, Tiziana, Novello, Silvia*

مصطلحات موضوعية: alectinib, alectinib clinical trial, ALK, ALK inhibitor, ALK-rearranged NSCLC, ALK–TKI, ALK–tyrosine kinase inhibitor, EML4–ALK, non-small cell lung cancer, NSCLC, Oncology

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/30090122; info:eu-repo/semantics/altIdentifier/wos/WOS:000442650700001; volume:10; firstpage:///; lastpage:///; numberofpages:///; journal:THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY; http://hdl.handle.net/2318/1685288Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85054839982; http://tam.sagepub.com/content/by/yearTest

الإتاحة: https://doi.org/10.1177/1758835918789364Test
http://hdl.handle.net/2318/1685288Test
http://tam.sagepub.com/content/by/yearTest

المؤلفون: Xue Du, Yanhong Tai, Yi Ban, Han Zhang, Hai-Feng Qin, Hongjun Gao, Yun Shao, Xueli Zhang

المصدر: Cancer Biology & Therapy

مصطلحات موضوعية: 0301 basic medicine, Cancer Research, Methyltransferase, medicine.drug_class, Drug resistance, 03 medical and health sciences, 0302 clinical medicine, hemic and lymphatic diseases, medicine, Anaplastic lymphoma kinase, Anaplastic lymphoma kinase (ALK), ALK Rearrangement, Pharmacology, ALK-rearranged NSCLC, crizotinib, Bedside to Bench Report, CMTR1, Crizotinib, business.industry, fusion partner gene, ALK inhibitor, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Personalized oncology, Cancer research, Molecular Medicine, ALK-tyrosine kinase inhibitor (TKI), Non small cell, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::025d44a46fb81315a4fc49205cffb266Test
https://doi.org/10.1080/15384047.2018.1480282Test

المؤلفون: Tatjana Bundalo, Dagmar Krenbek, Romana Wass, Ulrike Setinek, Oliver Illini, Matthias Urban, Peter Errhalt, Maximilian Hochmair, Michael Schumacher, Christoph Weinlinger, Helmut Prosch, Hannah Fabikan, Arschang Valipour, Gudrun Absenger, Ewald Wöll, Markus Rauter, Elmar Brehm

المصدر: Pharmaceuticals
Volume 13
Issue 11
Pharmaceuticals, Vol 13, Iss 371, p 371 (2020)

مصطلحات موضوعية: Alectinib, Oncology, medicine.medical_specialty, Brigatinib, ALK-positive disease, Pharmaceutical Science, lcsh:Medicine, lcsh:RS1-441, Article, lcsh:Pharmacy and materia medica, lorlatinib, immune system diseases, Internal medicine, hemic and lymphatic diseases, Drug Discovery, medicine, Anaplastic lymphoma kinase, Lung cancer, Response rate (survey), business.industry, ROS1-positive disease, lcsh:R, medicine.disease, Lorlatinib, Sequential treatment, sequential treatment, ALK tyrosine kinase inhibitor treatment, Molecular Medicine, business, Tyrosine kinase

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a284bfd3e5d50d18a3a73b1be320563Test

المؤلفون: Du, Xue, Shao, Yun, Qin, Hai‐Feng, Tai, Yan‐Hong, Gao, Hong‐Jun

المصدر: Thoracic Cancer

مصطلحات موضوعية: Invited Review, Oncogene Proteins, Fusion, non‐small‐cell lung cancer (NSCLC), Serine Endopeptidases, ALK‐tyrosine kinase inhibitor (TKI), Kinesins, Cell Cycle Proteins, respiratory tract diseases, Nuclear Pore Complex Proteins, anaplastic lymphoma kinase (ALK), Crizotinib, Drug Resistance, Neoplasm, hemic and lymphatic diseases, Carcinoma, Non-Small-Cell Lung, Proto-Oncogene Proteins, Humans, Anaplastic Lymphoma Kinase, ALK‐rearrangement (ALK‐R), detection platforms, Microtubule-Associated Proteins, Nucleophosmin, Protein Kinase Inhibitors

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=pmid________::757d5cda14e064ba2a0d21968aea2181Test
http://europepmc.org/articles/PMC5879058Test

المؤلفون: Annapaola Mariniello, Silvia Novello, Tiziana Vavalà

المصدر: Translational Cancer Research

مصطلحات موضوعية: ALK inhibitors, Cancer Research, medicine.drug_class, Non-small cell lung cancer (NSCLC), Review Article, medicine.disease_cause, hemic and lymphatic diseases, medicine, Anaplastic lymphoma kinase, Radiology, Nuclear Medicine and imaging, Lung cancer, Mutation, Crizotinib, business.industry, medicine.disease, Reverse transcriptase, respiratory tract diseases, ALK inhibitor, anaplastic lymphoma kinase (ALK), Oncology, ALK tyrosine kinase inhibitor (ALK-TKI), Cancer research, Signal transduction, business, Tyrosine kinase, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70d8f439a48f1f1b6d9bed768e47e2d8Test
http://hdl.handle.net/2318/1687660Test

المؤلفون: Jiyeon Hyeon, Jongmin Sim, Joungho Han, Yoon-La Choi, Hyunjin Kim

المصدر: Journal of Korean Medical Science

مصطلحات موضوعية: 0301 basic medicine, Adult, Male, Lung Neoplasms, Adenocarcinoma, Neuroendocrine differentiation, 03 medical and health sciences, 0302 clinical medicine, hemic and lymphatic diseases, Medicine, Anaplastic lymphoma kinase, Humans, Anaplastic Lymphoma Kinase, Epidermal growth factor receptor, Sulfones, Oncology & Hematology, Histologic Transformation, Protein Kinase Inhibitors, In Situ Hybridization, Fluorescence, Aged, ALK-tyrosine Kinase Inhibitor, Ceritinib, biology, Crizotinib, business.industry, Receptor Protein-Tyrosine Kinases, General Medicine, Middle Aged, medicine.disease, Immunohistochemistry, CD56 Antigen, respiratory tract diseases, ErbB Receptors, 030104 developmental biology, Pyrimidines, 030220 oncology & carcinogenesis, Mutation, Cancer research, biology.protein, Female, Original Article, business, Tyrosine kinase, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cca58eb1b53757d579183a849fb43ceTest
https://pubmed.ncbi.nlm.nih.gov/29629521Test